Ligand Pharmaceuticals Inc (LGND) · Aug 6, 2026 · Company update

Royalty growth beat estimates as XOMA synergies lift 2026 EPS floor

Royalty growth beat estimates as XOMA synergies lift 2026 EPS floor

Expectations were for roughly $62.8 million of revenue and about $1.92–$2.00 of adjusted EPS; Ligand cleared both. Second-quarter revenue was $63.7 million and adjusted diluted EPS was $2.37, versus year-ago figures of $47.6 million and $1.60, respectively. That makes the revenue beat modest, but the EPS beat meaningful; published estimates clustered near those levels.

MetricQ2 2026Q2 2025Versus expectation
Total revenues and income$63.7M$47.6MAbove roughly $62.8M consensus
Royalties$48.0M$36.4M32% year over year (Financial Statements)
Adjusted net income$50.8M$32.0M59% year over year (Adjusted Net Income reconciliation)
Adjusted diluted EPS$2.37$1.60Above roughly $1.92–$2.00 consensus
Cash, cash equivalents and short-term investments$1.36B$733.5M at Dec. 31, 2025Up after debt financing (Balance Sheet)
2026 adjusted core EPS guidance$9.00–$9.50Previously $8.50–$9.50Low end raised by $0.50 (Financial Outlook)

The underlying earnings quality was better than the headline GAAP profit suggests. Royalty revenue, the core recurring engine, rose 32% to $48.0 million, led by Filspari, Zelsuvmi and Ohtuvayre; Filspari’s partner also reported 96% year-over-year product-sales growth, while Ohtuvayre and Capvaxive continued to scale. Captisol revenue slipped to $8.0 million, and the quarter’s $35.7 million gain on Pelthos-related investments was non-cash, but adjusted EPS still reached $2.37 after excluding that volatility (Financial Highlights; Partner Product Updates; Adjusted Net Income reconciliation).

The guidance move is the clearest incremental positive. Ligand reaffirmed 2026 revenue guidance of $270 million–$310 million but raised the low end of adjusted core EPS guidance to $9.00 from $8.50, citing stronger XOMA cost synergies, additional interest income from the 0% convertible notes and the share repurchase (Financial Outlook). Because the revenue range was unchanged, the upgrade is primarily a profitability and capital-structure benefit rather than a demand reset.

XOMA now moves from transaction promise to operating contribution, but the financing adds leverage. The acquisition closed on schedule and is expected to contribute roughly $0.50 per share to 2026 adjusted EPS and $1.50 in 2027, while more than doubling Ligand’s royalty portfolio to over 200 assets (Business Update). At the same time, convertible senior notes rose to $1.13 billion from $446.2 million at year-end, so the stronger cash balance reflects financing proceeds rather than operating cash generation alone (Balance Sheet). The net read is positive: a clear EPS beat, a higher earnings floor and improving royalty momentum, tempered by greater debt and continued reliance on partner execution.

Original filing on SEC EDGAR

More Ligand Pharmaceuticals Inc news

Royalty growth beat estimates as XOMA synergies lift 2026 EPS floor | LGND Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.